HHS peptide policy hands doctors the risk on six unapproved peptides

The new HHS peptide policy lets licensed pharmacies and doctors compound six unapproved peptides without federal action, but it puts the hardest call on the person who signs the prescription. The HHS peptide policy covers BPC 157, epitalon, KPV, MOTS c, semax and TB 500, and every fill still needs a prescription for a named patient. None of the six is an approved drug. FDA scientists opposed the move, according to Associated Press reporting cited by Healio, and one emergency physician warns that many patients will mistake it for an FDA endorsement.

What HHS will tolerate and on what terms

In its published policy text, HHS says it does not intend to take action against a state licensed pharmacy, a federal facility or a licensed physician that compounds a drug from one of six listed peptide ingredients, as long as every condition is met. The stated goal is "to expand and improve patient access while FDA reviews these substances." The pause runs until a final rule decides whether each peptide joins the 503A bulks list, the set of ingredients pharmacies may use when no approved drug or official monograph covers them. HHS adds that it may revisit the policy, in whole or in part, if a safety signal or a product quality problem appears. It is an enforcement choice, not an approval, and it can be withdrawn.

The conditions run to ten points. The ingredient must match the identity and route limits HHS set for each peptide, come from an FDA registered facility and arrive with a valid certificate of analysis covering identity, purity, potency and contaminants such as endotoxins and heavy metals. The original manufacturer, not only a repacker or distributor, must be registered and follow good manufacturing practice. Each product may contain just one listed peptide, must carry the line "This is a compounded drug product. Not for resale." and may be packed only with an FDA cleared syringe. Oral versions need records showing the formula is absorbed in humans. Compounders must also report serious adverse events and quality problems to FDA, through MedWatch reporting, and to the states involved.

Why prescribers now carry the weight

Owais Durrani, an emergency medicine physician in Houston, said in comments to Healio that the change could help people who already inject these peptides, because a prescription filled by a registered pharmacy is "a lot safer than a vial from an overseas website where purity can be anyone's guess." His larger worry is how the public hears the news. "Most patients will take it as an FDA endorsement, even though HHS has said it isn't one, and telehealth companies are ready to scale it quickly," he said. He added that some of the compounds act on tissue growth and cellular aging, where the long term questions include cancer risk and there is very little human data to answer them.

Durrani said that requirement moves responsibility onto the physician who signs, and he urged prescribers to obtain real informed consent, document it and report any adverse events.

The policy keeps the 503A rule that each compounded product must follow a valid prescription written for a specific patient. Durrani said that requirement moves responsibility onto the physician who signs, and he urged prescribers to obtain real informed consent, document it and report any adverse events. "Declining to prescribe these is a completely reasonable choice," he said. He noted that most of the six were reviewed for narrow uses such as ulcerative colitis or wound healing, while patients tend to ask about joints, recovery and longevity. The policy text sets sourcing, testing, labeling and reporting terms, but it gives prescribers no dosing guidance. Durrani said there is still no established dose or long term safety data for any of the six peptides, and that clinicians should expect patients who believe the products are cleared by FDA.

503A compounding limits differ for each peptide

HHS did not treat the six alike. Appendix B of the policy names the exact chemical form and the routes covered for each peptide, so 503A compounding of any other form or route falls outside the pause. For every one of the six, the document records that CDER, the FDA drug center, recommended against listing it, while the advisory committee voted in favor. HHS gave three broad reasons for setting that advice aside: new certificates of analysis from registered plants that fill gaps CDER had flagged, better records of how widely the peptides are already used, and its view that several CDER safety concerns were theoretical rather than observed. All six had sat in FDA's Category 2 group of flagged ingredients until April 22, 2026.

Lawyers at the firm Vedder, writing on JD Supra, point out that FDA already runs a broader interim policy for nominated bulk ingredients, and that what stands out here is a named list with conditions for each substance. They also cite an HHS statement that future rulemaking may propose adding some or all six peptides to the permanent list. Before release, the draft went through White House review, the lawyers note. The HHS peptide policy gives no end date, and the document does not say when it takes effect, how many pharmacies are expected to take part or what a patient will pay. It also says nothing about insurance, so no payer has been told to cover these products.

FDA scientists objected and the gray market remains

According to Associated Press reporting cited by Healio, FDA scientists had little input on the decision and opposed the changes. Citing six people familiar with the matter, the AP said agency staff pushed back hard and warned the policy could weaken FDA's long standing work of keeping unsafe products off the US market. Durrani said the Secretary went around the listing process, which in his words "skips the rulemaking and public comment that a formal listing would have required." At the July advisory meeting, Matthew Lash, acting director of FDA's Office of Compounding Quality and Compliance, said compounded drugs are overseen mainly by state regulators and have not been reviewed by FDA for safety, efficacy or manufacturing quality before they are sold.

HHS presents the HHS peptide policy as a way to pull patients away from research use only peptides made by foreign suppliers, which it says pose a safety risk to US patients. Whether that happens depends on whether pharmacies can meet the sourcing and testing terms, and on whether buyers move from overseas vials to prescribed products. Our earlier report on BPC 157 compounding found the human evidence still thin. For patients, the basic facts have not changed: none of the six is approved, a compounded product carries no FDA review of safety or quality, and its label must say it is compounded. Anyone who has a serious reaction to a compounded peptide can report it to FDA through MedWatch.

Conclusion

The HHS peptide policy opens a legal lane for six unapproved peptides at licensed pharmacies, but only under strict sourcing, labeling and reporting terms, and only with a prescription. It does not approve any of them, set a dose, fix a price or bind an insurer, and HHS says it can pull back if safety or quality problems surface. The open questions are the start date, how many pharmacies qualify and whether FDA scientists' concerns shape the final rule.